| Barchart Demo Center |
$2,64
+0,62 (+30,69%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 2,64 |
|---|---|
| Variation | +0,62 (+30,69%) |
| Ouverture | 2,03 |
| Clôture précédente | 2,02 |
| Écart (actuel) |
1,99
3,08
|
| Écart 52 semaines |
1,30
13,20
|
| Volume | 2 367 100 |
| Volume Moyen | 266 785 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| CYCC |
 +30,69% |
 +17,34% |
 -73,37% |
| DJIA |
+1,51% |
-2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | -22,44 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 3 000 |
| Alpha pondéré | -74,49 |
| Écart-type | +2,75 |
| Marge d'exploitation | -4 401,34% |
| Beta | 0,54 |
Taux de croissance
| Cette année | -1,12% | |||
| 1 An(s) | -72,92% | |||
| 3 An(s) | -97,40% | |||
| 5 An(s) | -98,43% | |||
| 10 An(s) | -99,98% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Cyclacel Pharmaceuticals to Release First Quarter 2024
GlobeNewswire - Wed May 08, 08:15AM CDT
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(version intégrale)
Cyclacel Pharmaceuticals Announces Closing of $8.0
GlobeNewswire - Thu May 02, 03:30PM CDT
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(version intégrale)
Cyclacel Pharmaceuticals Announces $8.0 Million
GlobeNewswire - Tue Apr 30, 06:00AM CDT
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(version intégrale)
Cyclacel Pharmaceuticals to Present New Clinical Data
GlobeNewswire - Mon Apr 01, 08:15AM CDT
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...(version intégrale)
Cyclacel Pharmaceuticals Reports Fourth Quarter and
GlobeNewswire - Tue Mar 19, 03:05PM CDT
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – ...(version intégrale)